{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:07:47Z","timestamp":1784286467983,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir\/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir\/ritonavir; 250 who took nirmatrelvir\/ritonavir and 250 who did not. The primary outcome was the development of one or more of eleven prespecified long COVID symptoms, assessed through a structured telephone interview four months after the positive SARS-CoV-2 test. Multivariable logistic regression models controlled for age, sex, race\/ethnicity, chronic conditions, and COVID-19 vaccination status. We found that participants who took nirmatrelvir\/ritonavir were no less likely to develop long COVID symptoms, compared to those who did not take the medication (44% vs. 49.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.21). Taking nirmatrelvir\/ritonavir was associated with a lower odds of two of the eleven long COVID symptoms, brain fog (OR 0.58, 95% CI 0.38\u20130.88) and chest pain\/tightness (OR 0.51, 95% CI 0.28\u20130.91). Our finding that treatment with nirmatrelvir\/ritonavir was not associated with a lower risk of developing long COVID is different from prior studies that obtained data only from electronic medical records.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-46912-4","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T06:01:39Z","timestamp":1699682499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Nirmatrelvir\/ritonavir and risk of long COVID symptoms: a retrospective cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Seth","family":"Congdon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Narrowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nang","family":"Yone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Nori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsie","family":"Cowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Rikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Starrels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"46912_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615. https:\/\/doi.org\/10.1038\/s41591-021-01283-z (2021).","journal-title":"Nat. Med."},{"key":"46912_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28568","author":"D Groff","year":"2021","unstructured":"Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28568 (2021).","journal-title":"JAMA Netw Open."},{"key":"46912_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100122","volume":"6","author":"M Augustin","year":"2021","unstructured":"Augustin, M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 6, 100122. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100122 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"46912_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072117","volume":"378","author":"T Greenhalgh","year":"2022","unstructured":"Greenhalgh, T., Sivan, M., Delaney, B., Evans, R. & Milne, R. Long covid-an update for primary care. BMJ. 378, e072117. https:\/\/doi.org\/10.1136\/bmj-2022-072117 (2022).","journal-title":"BMJ."},{"key":"46912_CR5","unstructured":"Department of Health and Human Services, Office of the Assistant Secretary for Health. National Research Action Plan on Long COVID. Available at: https:\/\/www.covid.gov\/assets\/files\/National-Research-Action-Plan-on-Long-COVID-08012022.pdf\/. Accessed December 20, 2022 Dec 20."},{"key":"46912_CR6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.mayocp.2021.04.024","volume":"96","author":"G Vanichkachorn","year":"2021","unstructured":"Vanichkachorn, G. et al. Post-COVID-19 syndrome (long haul syndrome): Description of a multidisciplinary clinic at mayo clinic and characteristics of the initial patient cohort. Mayo Clin. Proc. 96, 1782\u20131791. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.024 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"46912_CR7","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/s41467-022-29513-z","volume":"13","author":"VT Tran","year":"2022","unstructured":"Tran, V. T., Porcher, R., Pane, I. & Ravaud, P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat. Commun. 13, 1812. https:\/\/doi.org\/10.1038\/s41467-022-29513-z (2022).","journal-title":"Nat. Commun."},{"key":"46912_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2213-2600(22)00127-8","volume":"10","author":"PHOSP-COVID Collaborative Group","year":"2022","unstructured":"PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir. Med. 10, 761\u2013775. https:\/\/doi.org\/10.1016\/S2213-2600(22)00127-8 (2022).","journal-title":"Lancet Respir. Med."},{"key":"46912_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","volume":"10","author":"L Huang","year":"2022","unstructured":"Huang, L. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Respir Med. 10, 863\u2013876. https:\/\/doi.org\/10.1016\/S2213-2600(22)00126-6 (2022).","journal-title":"Lancet Respir Med."},{"key":"46912_CR10","unstructured":"U.S. Census Bureau. Long COVID Household Pulse Survey, 2022\u20132023. Available at: https:\/\/www.cdc.gov\/nchs\/covid19\/pulse\/long-covid.htm\/. Accessed July 20, 2023."},{"key":"46912_CR11","unstructured":"Bach, K. New Data shows long Covid is keeping as many as 4 million people out of work. Available at: https:\/\/www.brookings.edu\/research\/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work\/. Accessed December 28, 2022."},{"key":"46912_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","volume":"183","author":"V Tsampasian","year":"2023","unstructured":"Tsampasian, V. et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Inter. Med. 183, 566\u2013580. https:\/\/doi.org\/10.1001\/jamainternmed.2023.0750 (2023).","journal-title":"JAMA Inter. Med."},{"key":"46912_CR13","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1038\/s41467-021-26513-3","volume":"12","author":"Y Xie","year":"2021","unstructured":"Xie, Y., Bowe, B. & Al-Aly, Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 12, 6571. https:\/\/doi.org\/10.1038\/s41467-021-26513-3 (2021).","journal-title":"Nat. Commun."},{"key":"46912_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/cid\/ciac818","volume":"76","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Nasal and plasma severe acute respiratory syndrome coronavirus 2 RNA levels are associated with timing of symptom resolution in the ACTIV-2 trial of nonhospitalized adults with coronavirus disease 2019. Clin Infect Dis. 76, 734\u2013737. https:\/\/doi.org\/10.1093\/cid\/ciac818 (2023).","journal-title":"Clin Infect Dis."},{"key":"46912_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","volume":"185","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 185, 881\u2013895. https:\/\/doi.org\/10.1016\/j.cell.2022.01.014 (2022).","journal-title":"Cell."},{"key":"46912_CR16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542 (2022).","journal-title":"N. Engl. J. Med."},{"key":"46912_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 183, 554\u2013564. https:\/\/doi.org\/10.1001\/jamainternmed.2023.0743 (2023).","journal-title":"JAMA Intern. Med."},{"key":"46912_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11098","volume":"6","author":"DJ Lundberg","year":"2023","unstructured":"Lundberg, D. J. et al. COVID-19 mortality by race and ethnicity in US metropolitan and nonmetropolitan areas, March 2020 to February 2022. JAMA Netw. Open. 6, e2311098. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.11098 (2023).","journal-title":"JAMA Netw. Open."},{"key":"46912_CR19","doi-asserted-by":"publisher","first-page":"05015","DOI":"10.7189\/jogh.11.05015","volume":"11","author":"W Mude","year":"2021","unstructured":"Mude, W., Oguoma, V. M., Nyanhanda, T., Mwanri, L. & Njue, C. Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. J. Glob. Health. 11, 05015. https:\/\/doi.org\/10.7189\/jogh.11.05015 (2021).","journal-title":"J. Glob. Health."},{"key":"46912_CR20","unstructured":"U.S. Census Bureau. QuickFacts, Bronx County, New York. Available at: https:\/\/www.census.gov\/quickfacts\/fact\/table\/bronxcountynewyork\/PST045221. Accessed December 28, 2022."},{"key":"46912_CR21","unstructured":"Food and Drug Administration. Fact Sheet For Healthcare Providers: Emergency Use Authorization for PaxlovidTM. Available at: https:\/\/www.fda.gov\/media\/155050\/download. Accessed December 28, 2022."},{"key":"46912_CR22","unstructured":"Centers For Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html. Accessed December 28, 2022."},{"key":"46912_CR23","unstructured":"National Institute of Health. Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid-\/paxlovid-drug-drug-interactions\/. Accessed December 28, 2022."},{"key":"46912_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38804","author":"RH Perlis","year":"2022","unstructured":"Perlis, R. H. et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.38804 (2022).","journal-title":"JAMA Netw. Open"},{"key":"46912_CR25","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","volume":"328","author":"S Wulf Hanson","year":"2022","unstructured":"Wulf Hanson, S. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328, 1604\u20131615. https:\/\/doi.org\/10.1001\/jama.2022.18931 (2022).","journal-title":"JAMA"},{"key":"46912_CR26","unstructured":"COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18."},{"key":"46912_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/cid\/ciab352","volume":"74","author":"VT Tran","year":"2022","unstructured":"Tran, V. T. et al. Development and validation of the long coronavirus disease (COVID) symptom and impact tools: A set of patient-reported instruments constructed from patients\u2019 lived experience. Clin. Infect. Dis. 74, 278\u2013287. https:\/\/doi.org\/10.1093\/cid\/ciab352 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"46912_CR28","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1038\/s41467-022-33415-5","volume":"13","author":"CE Hastie","year":"2022","unstructured":"Hastie, C. E. et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat. Commun. 13, 5663. https:\/\/doi.org\/10.1038\/s41467-022-33415-5 (2022).","journal-title":"Nat. Commun."},{"key":"46912_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.36057","author":"MS Durstenfeld","year":"2022","unstructured":"Durstenfeld, M. S. et al. Use of cardiopulmonary exercise testing to evaluate long COVID-19 symptoms in adults: A systematic review and meta-analysis. JAMA Netw. Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36057 (2022).","journal-title":"JAMA Netw. Open."},{"key":"46912_CR30","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1038\/s41467-022-35240-2","volume":"13","author":"K Magnusson","year":"2022","unstructured":"Magnusson, K. et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs. Delta variants. Nat. Commun. 13, 7363. https:\/\/doi.org\/10.1038\/s41467-022-35240-2 (2022).","journal-title":"Nat. Commun."},{"key":"46912_CR31","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2023.8823","volume":"329","author":"T Thaweethai","year":"2023","unstructured":"Thaweethai, T. et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 329, 1934\u20131946. https:\/\/doi.org\/10.1001\/jama.2023.8823 (2023).","journal-title":"JAMA"},{"key":"46912_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","volume":"12","author":"AD Proal","year":"2021","unstructured":"Proal, A. D. & VanElzakker, M. B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 12, 698169. https:\/\/doi.org\/10.3389\/fmicb.2021.698169 (2021).","journal-title":"Front. Microbiol."},{"key":"46912_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146. https:\/\/doi.org\/10.1038\/s41579-022-00846-2 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"46912_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","volume":"71","author":"TK Boehmer","year":"2022","unstructured":"Boehmer, T. K. et al. Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January\u2013July 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 1359\u20131365. https:\/\/doi.org\/10.15585\/mmwr.mm7143a2 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"46912_CR35","unstructured":"Ndugga, N., Hill, L. & Artiga, S. COVID-19 Cases and Deaths, Vaccinations and Treatments by Race\/Ethnicity as of Fall 2022. Available at: https:\/\/www.kff.org\/racial-equity-and-health-policy\/issue-brief\/covid-19-cases-and-deaths-vaccinations-and-treatments-by-race-ethnicity-as-of-fall-2022\/. Accessed December 28, 2022."},{"key":"46912_CR36","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.eclinm.2022","volume":"53","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 53, 101624. https:\/\/doi.org\/10.1016\/j.eclinm.2022 (2022).","journal-title":"EClinicalMedicine."},{"key":"46912_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.51360","volume":"6","author":"SA Richard","year":"2022","unstructured":"Richard, S. A. et al. Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw. Open. 6, e2251360. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.51360 (2022).","journal-title":"JAMA Netw. Open."},{"key":"46912_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bbi.2021.12.020","volume":"101","author":"F Ceban","year":"2022","unstructured":"Ceban, F. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 101, 93\u2013135. https:\/\/doi.org\/10.1016\/j.bbi.2021.12.020 (2022).","journal-title":"Brain Behav. Immun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46912-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T06:08:16Z","timestamp":1699682896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46912-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46912"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46912-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3231786\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19688"}}